Fundraising FoxEndonovo Therapeutics
OTC: ENDVWoodland Hills, US · Founded 2011 · Delaware corporation
Find your way into Endonovo Therapeutics
Sign up to see every warm intro you have to Endonovo Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Endonovo Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Endonovo Therapeutics is a commercial-stage developer of non-invasive, wearable medical devices that deliver its Electroceutical Therapy, which uses bioelectricity to treat inflammatory conditions, cardiovascular diseases, and central nervous system disorders. Its therapy is FDA-cleared and CE-marked for pain, post-surgical edema, and wound healing, with a clinical-stage pipeline targeting ischemic heart disease, concussions, traumatic brain injury, and multiple sclerosis.
Founders & leadership
MM
Michael MannExecutive
AC
Alan CollierExecutiveAlan Collier has over three decades of experience in corporate finance, accounting, and computer science, with expertise in strategic planning, mergers and acquisitions, business development, and capital financing. He serves as an Executive Officer and Director at Endonovo Therapeutics, a developer of wearable electroceutical medical devices for inflammatory and cardiovascular conditions.
Reported raises · per SEC filings
Form D private placements$1.8M disclosed across 7 of 9 rounds · 2013–2019
▶$225KraisedNov 2019 · 4 investors · BiotechnologyRule 506(c)
▶$225KraisedNov 2019 · 4 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Collier CollierExecutive Officer, Director
- Michael MannExecutive Officer
- Offering amount
- $2M
- Amount sold
- $225K
- Minimum investment
- $25K
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$700KraisedDec 2017 · 13 investors · BiotechnologyRule 506(c)
▶$700KraisedDec 2017 · 13 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Michael MannExecutive Officer
- Alan CollierExecutive Officer, Director
- Offering amount
- $8M
- Amount sold
- $700K
- Minimum investment
- $25K
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$211.3KraisedFeb 2016 · 6 investors · OtherRule 506(c)
▶$211.3KraisedFeb 2016 · 6 investors · Other
Rule 506(c)Officers, directors & promoters on the filing
- Michael MannExecutive Officer
- Alan CollierExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $211.3K
- Minimum investment
- $5K
- Proceeds to insiders
- $50K
- First sale
- Jan 2016
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06c
▶$105KraisedDec 2014 · 3 investors · OtherRule 506(c)
▶$105KraisedDec 2014 · 3 investors · Other
Rule 506(c)Officers, directors & promoters on the filing
- Michael MannExecutive Officer
- Alan CollierExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $105K
- Minimum investment
- $5K
- Proceeds to insiders
- $20K
- First sale
- Nov 2014
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06c
▶$12.5KraisedDec 2014 · 1 investors · Other
▶$12.5KraisedDec 2014 · 1 investors · Other
Officers, directors & promoters on the filing
- Alan CollierExecutive Officer, Director
- Michael MannExecutive Officer
- Offering amount
- $25K
- Amount sold
- $12.5K
- Minimum investment
- $5K
- First sale
- Sep 2014
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 05
▶$50KraisedDec 2014 · 2 investors · OtherRule 506(c)
▶$50KraisedDec 2014 · 2 investors · Other
Rule 506(c)Officers, directors & promoters on the filing
- Michael MannExecutive Officer
- Alan CollierExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $50K
- Minimum investment
- $5K
- Proceeds to insiders
- $20K
- First sale
- Aug 2014
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06c
▶$483KraisedAug 2014 · 19 investors · BiotechnologyRule 506(c)
▶$483KraisedAug 2014 · 19 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Alan CollierExecutive Officer, Director
- Michael MannExecutive Officer
- Offering amount
- $500K
- Amount sold
- $483K
- Minimum investment
- $5K
- Proceeds to insiders
- $100K
- First sale
- Oct 2013
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Endonovo Therapeutics do?
- Endonovo Therapeutics is a commercial-stage developer of non-invasive, wearable medical devices that deliver its Electroceutical Therapy, which uses bioelectricity to treat inflammatory conditions, cardiovascular diseases, and central nervous system disorders. Its therapy is FDA-cleared and CE-marked for pain, post-surgical edema, and wound healing, with a clinical-stage pipeline targeting ischemic heart disease, concussions, traumatic brain injury, and multiple sclerosis.
- How much funding has Endonovo Therapeutics raised?
- Endonovo Therapeutics has disclosed $1.8M raised across 7 of its 9 known rounds.
- Where is Endonovo Therapeutics headquartered?
- Endonovo Therapeutics is headquartered in Woodland Hills, US.